Get the Stockscreener App
7.11
3.27%
-0.24
Sagimet Biosciences Inc stock is traded at $7.11, with a volume of 477.37K.
It is down -3.27% in the last 24 hours and down -25.94% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$7.35
Open:
$7.35
24h Volume:
477.37K
Relative Volume:
0.32
Market Cap:
$220.42M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-5.9949
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
-7.30%
1M Performance:
-25.94%
6M Performance:
+72.57%
1Y Performance:
+144.33%
1-Day Range:
$7.03
$7.48
1-Week Range:
$6.5323
$8.013
52-Week Range:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.11 | 245.54M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) - ca.finance.yahoo.com
Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy - TipRanks
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Promising Growth Potential of Sagimet Biosciences: Buy Rating Justified by Strategic Trials and Strong Financial Position - TipRanks
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know - MSN
Will earnings trigger a reversal in Sagimet Biosciences Inc.Earnings Overview Report & Real-Time Buy Zone Alerts - Newser
How sentiment analysis helps forecast Sagimet Biosciences Inc.July 2025 Review & Capital Protection Trading Alerts - Newser
Real time scanner hits for Sagimet Biosciences Inc. explained2025 Performance Recap & Real-Time Buy Signal Alerts - Newser
What data driven models say about Sagimet Biosciences Inc.’s futureShare Buyback & High Accuracy Swing Trade Signals - Newser
Is Sagimet Biosciences Inc. stock bottoming outInsider Buying & Free Verified High Yield Trade Plans - Newser
Sagimet Biosciences Inc. recovery potential after sell offWeekly Loss Report & Free Growth Oriented Trading Recommendations - Newser
Screener Results Flag Sagimet Biosciences Inc. as OversoldEarnings Growth Summary & Risk Controlled Stock Alerts - beatles.ru
News impact scoring models applied to Sagimet Biosciences IncEarnings Overview Report & Low Drawdown Trading Techniques - Newser
Is Sagimet Biosciences Inc. building a consolidation baseJuly 2025 Patterns & Fast Entry High Yield Tips - Newser
How high can Sagimet Biosciences Inc. stock price go in 2025Earnings Miss & Real-Time Volume Trigger Notifications - Newser
News impact scoring models applied to Sagimet Biosciences Inc.July 2025 Outlook & Precise Trade Entry Recommendations - Newser
How Sagimet Biosciences Inc. stock performs during market volatilityBull Run & Daily Risk Controlled Trade Plans - Newser
Will Sagimet Biosciences Inc. Benefit From Sector TailwindsTrade Signal Summary & Real-Time Volume Trigger Notifications - metal.it
A Quick Look at Today's Ratings for Sagimet Biosciences(SGMT.US), With a Forecast Between $25 to $29 - 富途牛牛
Sagimet Biosciences: Promising Advancements in FASN Inhibitor Platform and Strategic Growth Initiatives Justify Buy Rating - TipRanks
Promising Potential of Sagimet Biosciences’ FASN Inhibitors Drives Buy Rating - TipRanks
Brokers Set Expectations for SGMT Q2 Earnings - Defense World
Sagimet Biosciences Advances FASN Inhibitor Trials for Acne and MASH, Reports Q2 Earnings - AInvest
Sagimet Biosciences Reports Progress in Acne and MASH Trials - TipRanks
Sagimet Biosciences Enters New Sales Agreement with Leerink - TipRanks
Sagimet Biosciences Reports Q2 Results and Clinical Progress - MSN
Sagimet Biosciences enters $75 million at-the-market sales agreement with Leerink Partners - Investing.com Canada
Sagimet Biosciences enters $75 million at-the-market sales agreement with Leerink Partners By Investing.com - Investing.com South Africa
Sagimet Biosciences, Inc. Class A: Promising Combination Therapy for MASH Drives Buy Rating - TipRanks
Sagimet Biosciences Tops Q2 EPS Forecast - AOL.com
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Q2 GAAP EPS Beats by $0.21, Cash Holdings at $135.5M - AInvest
Sagimet Biosciences: Navigating the High-Risk Biopharma Landscape with Operational Gains and Earnings Resilience - AInvest
Sagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates - Nasdaq
Sagimet Reports Q1 Earnings, Advances Denifanstat and TVB-3567 Trials - AInvest
Sagimet Biosciences Inc. SEC 10-Q Report - TradingView
Wedbush Begins Coverage on Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Wedbush Initiates Sagimet Biosciences at Outperform With $28 Price Target - MarketScreener
Wedbush initiates coverage on Sagimet Biosciences with Outperform rating and $28 PT. - AInvest
Wedbush initiates coverage on Sagimet Biosciences stock with Outperform rating - Investing.com Nigeria
Can Sagimet Biosciences Inc. Escape Recent Bear ChannelDay Trading Signals With High Precision Reviewed - beatles.ru
Sagimet Biosciences (SGMT) to Release Quarterly Earnings on Wednesday - Defense World
What is HC Wainwright’s Estimate for SGMT Q2 Earnings? - Defense World
Sagimet Biosciences SGMT Q2 2025 Earnings Preview Upside Potential Driven by Strategic Innovations - AInvest
Sagimet Biosciences (NASDAQ:SGMT) Upgraded at HC Wainwright - Defense World
Is This a Bottoming Phase for Sagimet Biosciences Inc.Capital Protection Trading Strategies Gain Interest - beatles.ru
Can volume confirm reversal in Sagimet Biosciences Inc.Chart Driven Entry Timing for Swing Trades - Newser
Sagimet Biosciences Inc. Matches Institutional Buying FilterWeekly Chart Analysis With Entry Advice Provided - beatles.ru
How to recover losses in Sagimet Biosciences Inc. stockMachine Learning Intraday Signal Forecast - Newser
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sagimet Biosciences Inc Stock (SGMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 21 '25 |
Sale |
9.13 |
8,277 |
75,607 |
106,936 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 21 '25 |
Sale |
9.13 |
10,780 |
98,471 |
183,726 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):